Revolution Medicines (RVMD) Change in Accured Expenses (2019 - 2026)

Revolution Medicines has reported Change in Accured Expenses for 8 years, with the latest figure at -$16.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 1180.63% year-over-year to -$16.7 million; the trailing twelve-month figure through Mar 2026 stood at $94.0 million (up 109.81% YoY), and the FY2025 full-year result was $112.3 million, up 410.65% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$16.7 million, down from $54.6 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $54.6 million in Q4 2025, with the low at -$21.3 million in Q1 2024.
• Average Change in Accured Expenses over 5 years is $7.9 million, with a median of $7.6 million recorded in 2023.
• Year-over-year, Change in Accured Expenses soared 685.1% in 2023 and plunged 1180.63% in 2026.
• Tracing RVMD's Change in Accured Expenses over 5 years: stood at -$3.0 million in 2022, then sank by 112.1% to -$6.3 million in 2023, then jumped by 390.86% to $18.3 million in 2024, then jumped by 198.42% to $54.6 million in 2025, then sank by 130.66% to -$16.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$16.7 million (Q1 2026), $54.6 million (Q4 2025), and $45.3 million (Q3 2025), per Business Quant data.

Peer Comparison